Backed by Sean Harper and Beth Seidenberg, an LA biotech scores a massive $250M crossover ahead of 2022 IPO
When Acelyrin closed its Series A late last year, it was met with little fanfare. The biotech had only two employees, the former R&D chief and CBO of Horizon Therapeutics, and didn’t even disclose the size of the raise. Westlake Village BioPartners, an LA-based VC firm and lead investor, proved the most noteworthy aspect of the announcement, having spawned from ex-Amgen R&D head Sean Harper and ex-Kleiner Perkins life sciences director Beth Seidenberg.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,500+ biopharma pros reading Endpoints daily — and it's free.